ZURICH, July 21 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Tuesday:
Europe’s largest biotech company Actelion’s second quarter net profit rose 47 percent to 116 million Swiss francs ($108 million), helped by new patients and higher prices for key drug Tracleer and beat forecasts.
For related news click on [ATLN.VX]
U.S. regulators have approved Novartis’ Tekturna HCT combination as an initial treatment for patients who are unlikely to respond sufficiently to a single drug, the Swiss company said on Tuesday.
For related news click on [NOVN.VX]
Switzerland’s financial regulator FINMA is proposing measures to improve the capital base of cantonal and cooperative banks, it said on Monday.
For related news click on [BNK-CH]
* Swiss June trade data is due at 0615 GMT.
* The Swiss National bank issues is due to issue its statistical report at 0700 GMT.
COMPANY STATEMENTS [CNR-CH]
* Holcim HOLN.VX - Disclosure of shareholdings [HOLN.VX]
* Zurich ZURN.VX announces amount of preferred securities tendered via its Offer to Purchase as of the Early Tender Date [ZURN.VX]
EQUITY RESEARCH [CH-RCH]
FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:
.EX.S for all Swiss stocks
.EXSMI.S for blue chips
.EXNSMI.S for other stocks